Jane Street’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.23M | Buy |
+81,450
| New | +$1.23M | ﹤0.01% | 6096 |
|
|
2026
Q1 | – | Sell |
-319,814
| Closed | -$3.99M | – | 12559 |
|
|
2025
Q4 | $4.14M | Sell |
319,814
-102,466
| -24% | -$1.32M | ﹤0.01% | 3527 |
|
|
2025
Q3 | $5.46M | Buy |
422,280
+224,488
| +113% | +$3M | ﹤0.01% | 3300 |
|
|
2025
Q2 | $3.52M | Buy |
+197,792
| New | +$3.45M | ﹤0.01% | 3504 |
|
|
2024
Q4 | – | Sell |
-95,247
| Closed | -$2.02M | – | 10195 |
|
|
2024
Q3 | $1.49M | Sell |
95,247
-4,752
| -5% | -$86.2K | ﹤0.01% | 5064 |
|
|
2024
Q2 | $1.71M | Sell |
99,999
-466,883
| -82% | -$8.21M | ﹤0.01% | 4764 |
|
|
2024
Q1 | $8.86M | Buy |
566,882
+90,205
| +19% | +$1.33M | ﹤0.01% | 1943 |
|
|
2023
Q4 | $7.12M | Sell |
476,677
-68,414
| -13% | -$916K | ﹤0.01% | 2376 |
|
|
2023
Q3 | $8.8M | Buy |
545,091
+17,339
| +3% | +$500K | ﹤0.01% | 1919 |
|
|
2023
Q2 | $21.9M | Buy |
527,752
+359,289
| +213% | +$22.3M | 0.01% | 1126 |
|
|
2023
Q1 | $10.1M | Buy |
168,463
+152,920
| +984% | +$12.2M | ﹤0.01% | 1625 |
|
|
2022
Q4 | $1.14M | Buy |
15,543
+11,710
| +306% | +$881K | ﹤0.01% | 4773 |
|
|
2022
Q3 | $291K | Sell |
3,833
-272,585
| -99% | -$21.3M | ﹤0.01% | 7645 |
|
|
2022
Q2 | $19.2M | Buy |
276,418
+257,489
| +1,360% | +$19.4M | 0.01% | 1149 |
|
|
2022
Q1 | $1.57M | Sell |
18,929
-26,246
| -58% | -$1.93M | ﹤0.01% | 5221 |
|
|
2021
Q4 | $3.39M | Buy |
45,175
+35,059
| +347% | +$3.52M | ﹤0.01% | 3485 |
|
|
2021
Q3 | $1.18M | Sell |
10,116
-4,125
| -29% | -$624K | ﹤0.01% | 5593 |
|
|
2021
Q2 | $3.16M | Sell |
14,241
-9,902
| -41% | -$1.93M | ﹤0.01% | 3484 |
|
|
2021
Q1 | $3.19M | Sell |
24,143
-5,854
| -20% | -$926K | ﹤0.01% | 3132 |
|
|
2020
Q4 | $5.19M | Sell |
29,997
-6,291
| -17% | -$861K | ﹤0.01% | 2091 |
|
|
2020
Q3 | $4.04M | Sell |
36,288
-263,717
| -88% | -$21.1M | ﹤0.01% | 2093 |
|
|
2020
Q2 | $17.8M | Buy |
+300,005
| New | +$19.7M | 0.01% | 818 |
|
|
2020
Q1 | – | Sell |
-3,897
| Closed | -$308K | – | 5767 |
|
|
2019
Q4 | $328K | Sell |
3,897
-85,086
| -96% | -$6.87M | ﹤0.01% | 4178 |
|
|
2019
Q3 | $6.65M | Buy |
88,983
+73,941
| +492% | +$5.91M | 0.01% | 805 |
|
|
2019
Q2 | $951K | Buy |
15,042
+6,586
| +78% | +$334K | ﹤0.01% | 2763 |
|
|
2019
Q1 | $408K | Sell |
8,456
-4,756
| -36% | -$229K | ﹤0.01% | 3901 |
|
|
2018
Q4 | $442K | Buy |
+13,212
| New | +$483K | ﹤0.01% | 3596 |
|
|
2018
Q1 | – | Sell |
-22,759
| Closed | -$460K | – | 5213 |
|
|
2017
Q4 | $460K | Buy |
+22,759
| New | +$438K | ﹤0.01% | 3275 |
|
Other funds holding NVCR
SCM
QCM
Jane Street's NVCR Position: Q2 2026 in Review
Jane Street opened a new position in NovoCure (NVCR) in Q2 2026: 81,450 shares worth $1.23M. The stake represents ﹤0.01% of the portfolio and ranks #6096 among its holdings. This is a return to the name: Jane Street previously reported a position in NVCR as recently as Q4 2025.
Jane Street first reported a position in NVCR in Q4 2017 and has held it in 28 quarters since. The position peaked at $21.9M in Q2 2023. 199 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.
- Jane Street held 81,450 shares of NovoCure worth $1.23M as of Q2 2026.
- NovoCure was a new Jane Street position in Q2 2026.
- NovoCure made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #6096 holding.
- Jane Street first reported a position in NovoCure in Q4 2017 and has held it in 28 quarters since.
- Jane Street's NovoCure position peaked at $21.9M in Q2 2023.
- 199 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.